PODD · Insulet Corp · Investor Relations

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet’s global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. “We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes,” said Ashley McEvoy, Insulet President and Chief Executive Officer. “We are implementing thoughtful strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in building high-performing

Medical Device Correction impacts only specific lots of Omnipod® 5 Pods Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost All other Omnipod® 5 Pods and Omnipod® products remain safe to use Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use. Insulet identified that certain Pods from specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the Pod instead of being fully infused into the body as intended. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe